Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chronic Fatigue Syndrome AND Fatigue

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    156 result(s) found for: Chronic Fatigue Syndrome AND Fatigue. Displaying page 6 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2009-012367-34 Sponsor Protocol Number: BCX1812-301 Start Date*: 2009-11-27
    Sponsor Name:BioCryst Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard o...
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) NL (Ongoing) LV (Prematurely Ended) CZ (Completed) DE (Prematurely Ended) HU (Completed) GB (Prematurely Ended) SK (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005775-12 Sponsor Protocol Number: 230LE303 Start Date*: 2021-10-05
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Ba...
    Medical condition: systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006378-22 Sponsor Protocol Number: 230LE306 Start Date*: 2022-10-04
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants with Active Systemic Lupus Erythem...
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000425-40 Sponsor Protocol Number: GV29893 Start Date*: 2016-08-03
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, ADMINISTERED AS MONOTHERAPY FOR THE TREATMENT OF ACUTE UNCOMPLICATED SEASONAL INFLUENZA A INFECTION...
    Medical condition: acute uncomplicated seasonal influenza
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10022002 Influenza A virus infection LLT
    19.0 100000004862 10022001 Influenza (epidemic) LLT
    19.0 100000004862 10016790 Flu LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003778-34 Sponsor Protocol Number: VIP578 Start Date*: 2016-01-13
    Sponsor Name:Volution Immuno Pharmaceuticals (UK) Ltd
    Full Title: Coversin in Paroxysmal Nocturnal Haemoglobulinuria (PNH) in patients with resistance to Eculizumab due to complement C5 Polymorphisms
    Medical condition: Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in patients with resistance to Eculizumab due to complement C5 polymorphisms.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-003233-38 Sponsor Protocol Number: WA41937 Start Date*: 2021-03-02
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL ACTIVE COMPARATOR-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH PRIMARY MEMBRANOUS NEPHROPATHY
    Medical condition: Primary Membranous Nephropathy (pMN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002512-40 Sponsor Protocol Number: 201023 Start Date*: 2016-12-05
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin (GSK1325756) co-administered with a standard-of-care antiviral (oseltamivir), in the treatment of adults hospit...
    Medical condition: Hospitalized influenza
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) NL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002101-19 Sponsor Protocol Number: CACZ885X2206 Start Date*: 2016-11-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety and tolerability of ACZ885 (canakinumab) in pediatric and young adult pa...
    Medical condition: Sickle cell anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006504-32 Sponsor Protocol Number: ACTIV-2d/A5407 Start Date*: 2022-12-15
    Sponsor Name:Shionogi B.V.
    Full Title: A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19
    Medical condition: SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003740-74 Sponsor Protocol Number: V71_22 Start Date*: 2013-09-10
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Multi-Center, Phase IV, Randomized, Controlled, Observer Blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Trivalent Subunit Inactivated Influenza Vaccine in Healthy Subje...
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-013904-30 Sponsor Protocol Number: V111_04 Start Date*: 2009-07-14
    Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
    Full Title: A Phase II, Open Label Study to Evaluate the Immunogenicity, Tolerability and Safety of a MF59-Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Heal...
    Medical condition: Evaluate the Immunogenicity, Tolerability and Safety of a MF59-Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 Years and Above
    Disease: Version SOC Term Classification Code Term Level
    12.0 10022000 Influenza LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005526-35 Sponsor Protocol Number: 990 Start Date*: 2015-09-12
    Sponsor Name:Biotest AG
    Full Title: A Prospective, Double-blind, Randomized, Placebo-controlled, Repeated dose, Multicentre Phase IIa Proof-of-Concept Study with BT063 in Subjects with Systemic Lupus Erythematosus (BT063 in SLE)
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10042947 Systemic lupus erythematosus synd LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001868-19 Sponsor Protocol Number: 2015-001 Start Date*: 2015-10-15
    Sponsor Name:University medical center of Johannes Gutenberg University Mainz
    Full Title: A randomized, double-blind, placebo-controlled, mono-center study to evaluate the effects of mepolizumab on airway physiology in patients with eosinophilic asthma: the MEMORY study
    Medical condition: severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001737-27 Sponsor Protocol Number: 54767414AMY3001 Start Date*: 2018-04-16
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnos...
    Medical condition: AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis )
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000638-20 Sponsor Protocol Number: M19-130 Start Date*: 2020-01-22
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic ...
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) NL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003968-44 Sponsor Protocol Number: PCYC-1116-CA Start Date*: 2013-02-05
    Sponsor Name:Pharmacyclics LLC
    Full Title: An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib versus Chlo...
    Medical condition: Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10060669 B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) IE (Completed) CZ (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-006082-11 Sponsor Protocol Number: ADG20-TRMT-001 Start Date*: 2021-06-02
    Sponsor Name:Adagio Therapeutics Inc.
    Full Title: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP)
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) DE (Prematurely Ended) HU (Completed) BG (Prematurely Ended) PL (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-001645-41 Sponsor Protocol Number: JAK115919 Start Date*: 2013-02-19
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus.
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    16.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) GR (Completed) EE (Completed) CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003240-25 Sponsor Protocol Number: FIBHGM-ECNC003-2021 Start Date*: 2023-06-01
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Gregorio Marañón
    Full Title: PHASE I/IIa OPEN CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ALLOGENIC ADMINISTRATION OF TREG CELLS OBTAINED FROM THYMAL TISSUE (thyTreg) IN THE CONTROL OF IMMUNOLOGICAL HYPERACTIVATION ...
    Medical condition: immune hyperactivation in COVID-19 patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000226-58 Sponsor Protocol Number: A3921120 Start Date*: 2018-07-12
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 3, Randomized, Double Blind, Placebo Controlled, Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS)
    Medical condition: Ankylosing spondylitis (AS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) CZ (Completed) ES (Completed) AT (Prematurely Ended) GB (Completed) DE (Prematurely Ended) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Nov 06 20:18:33 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA